Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
18,515
archived clinical trials in
Lymphoma

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
A Phase II Study of Sequential Doxorubicin and Topotecan (Dox/Topo) in Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma (NHL)
Status: Enrolling
Updated:  7/7/2015
Comprehensive Cancer Center of Wake Forest University
2129
mi
from 91732
Winston-Salem, NC
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
A Phase II Study of Sequential Doxorubicin and Topotecan (Dox/Topo) in Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma (NHL)
Status: Enrolling
Updated: 7/7/2015
Comprehensive Cancer Center of Wake Forest University
2129
mi
from 91732
Winston-Salem, NC
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
A Phase II Study of Sequential Doxorubicin and Topotecan (Dox/Topo) in Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma (NHL)
Status: Enrolling
Updated:  7/7/2015
Veterans Affairs Medical Center - Fargo
1415
mi
from 91732
Fargo, ND
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
A Phase II Study of Sequential Doxorubicin and Topotecan (Dox/Topo) in Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma (NHL)
Status: Enrolling
Updated: 7/7/2015
Veterans Affairs Medical Center - Fargo
1415
mi
from 91732
Fargo, ND
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
A Phase II Study of Sequential Doxorubicin and Topotecan (Dox/Topo) in Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma (NHL)
Status: Enrolling
Updated:  7/7/2015
Arthur G. James Cancer Hospital - Ohio State University
1959
mi
from 91732
Columbus, OH
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
A Phase II Study of Sequential Doxorubicin and Topotecan (Dox/Topo) in Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma (NHL)
Status: Enrolling
Updated: 7/7/2015
Arthur G. James Cancer Hospital - Ohio State University
1959
mi
from 91732
Columbus, OH
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
A Phase II Study of Sequential Doxorubicin and Topotecan (Dox/Topo) in Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma (NHL)
Status: Enrolling
Updated:  7/7/2015
Lifespan: The Miriam Hospital
2563
mi
from 91732
Providence, RI
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
A Phase II Study of Sequential Doxorubicin and Topotecan (Dox/Topo) in Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma (NHL)
Status: Enrolling
Updated: 7/7/2015
Lifespan: The Miriam Hospital
2563
mi
from 91732
Providence, RI
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
A Phase II Study of Sequential Doxorubicin and Topotecan (Dox/Topo) in Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma (NHL)
Status: Enrolling
Updated:  7/7/2015
Veterans Affairs Medical Center - Dallas
1225
mi
from 91732
Dallas, TX
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
A Phase II Study of Sequential Doxorubicin and Topotecan (Dox/Topo) in Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma (NHL)
Status: Enrolling
Updated: 7/7/2015
Veterans Affairs Medical Center - Dallas
1225
mi
from 91732
Dallas, TX
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
A Phase II Study of Sequential Doxorubicin and Topotecan (Dox/Topo) in Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma (NHL)
Status: Enrolling
Updated:  7/7/2015
Green Mountain Oncology Group
2468
mi
from 91732
Bennington, VT
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
A Phase II Study of Sequential Doxorubicin and Topotecan (Dox/Topo) in Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma (NHL)
Status: Enrolling
Updated: 7/7/2015
Green Mountain Oncology Group
2468
mi
from 91732
Bennington, VT
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
A Phase II Study of Sequential Doxorubicin and Topotecan (Dox/Topo) in Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma (NHL)
Status: Enrolling
Updated:  7/7/2015
Vermont Cancer Center
2467
mi
from 91732
Burlington, VT
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
A Phase II Study of Sequential Doxorubicin and Topotecan (Dox/Topo) in Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma (NHL)
Status: Enrolling
Updated: 7/7/2015
Vermont Cancer Center
2467
mi
from 91732
Burlington, VT
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
A Phase II Study of Sequential Doxorubicin and Topotecan (Dox/Topo) in Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma (NHL)
Status: Enrolling
Updated:  7/7/2015
Veterans Affairs Medical Center - White River Junction
2511
mi
from 91732
White River Junction, VT
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
A Phase II Study of Sequential Doxorubicin and Topotecan (Dox/Topo) in Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma (NHL)
Status: Enrolling
Updated: 7/7/2015
Veterans Affairs Medical Center - White River Junction
2511
mi
from 91732
White River Junction, VT
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
A Phase II Study of Sequential Doxorubicin and Topotecan (Dox/Topo) in Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma (NHL)
Status: Enrolling
Updated:  7/7/2015
Martha Jefferson Hospital
2208
mi
from 91732
Charlottesville, VA
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
A Phase II Study of Sequential Doxorubicin and Topotecan (Dox/Topo) in Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma (NHL)
Status: Enrolling
Updated: 7/7/2015
Martha Jefferson Hospital
2208
mi
from 91732
Charlottesville, VA
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
A Phase II Study of Sequential Doxorubicin and Topotecan (Dox/Topo) in Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma (NHL)
Status: Enrolling
Updated:  7/7/2015
Virginia Oncology Associates - Norfolk
2341
mi
from 91732
Norfolk, VA
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
A Phase II Study of Sequential Doxorubicin and Topotecan (Dox/Topo) in Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma (NHL)
Status: Enrolling
Updated: 7/7/2015
Virginia Oncology Associates - Norfolk
2341
mi
from 91732
Norfolk, VA
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
A Phase II Study of Sequential Doxorubicin and Topotecan (Dox/Topo) in Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma (NHL)
Status: Enrolling
Updated:  7/7/2015
MBCCOP - Massey Cancer Center
2268
mi
from 91732
Richmond, VA
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
A Phase II Study of Sequential Doxorubicin and Topotecan (Dox/Topo) in Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma (NHL)
Status: Enrolling
Updated: 7/7/2015
MBCCOP - Massey Cancer Center
2268
mi
from 91732
Richmond, VA
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
A Phase II Study of Sequential Doxorubicin and Topotecan (Dox/Topo) in Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma (NHL)
Status: Enrolling
Updated:  7/7/2015
Oncology and Hematology Associates of Southwest Virginia
2133
mi
from 91732
Roanoke, VA
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
A Phase II Study of Sequential Doxorubicin and Topotecan (Dox/Topo) in Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma (NHL)
Status: Enrolling
Updated: 7/7/2015
Oncology and Hematology Associates of Southwest Virginia
2133
mi
from 91732
Roanoke, VA
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
A Phase II Study of Sequential Doxorubicin and Topotecan (Dox/Topo) in Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma (NHL)
Status: Enrolling
Updated:  7/7/2015
St Mary's Medical Center
1996
mi
from 91732
Huntington, WV
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
A Phase II Study of Sequential Doxorubicin and Topotecan (Dox/Topo) in Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma (NHL)
Status: Enrolling
Updated: 7/7/2015
St Mary's Medical Center
1996
mi
from 91732
Huntington, WV
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
A Phase II Study of Sequential Doxorubicin and Topotecan (Dox/Topo) in Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma (NHL)
Status: Enrolling
Updated:  7/7/2015
Ministry Medical Group - Northern Region
1701
mi
from 91732
Rhinelander, WI
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
A Phase II Study of Sequential Doxorubicin and Topotecan (Dox/Topo) in Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma (NHL)
Status: Enrolling
Updated: 7/7/2015
Ministry Medical Group - Northern Region
1701
mi
from 91732
Rhinelander, WI
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
A Phase II Study of Sequential Doxorubicin and Topotecan (Dox/Topo) in Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma (NHL)
Status: Enrolling
Updated:  7/7/2015
University of Puerto Rico School of Medicine Medical Sciences Campus
3353
mi
from 91732
San Juan,
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
A Phase II Study of Sequential Doxorubicin and Topotecan (Dox/Topo) in Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma (NHL)
Status: Enrolling
Updated: 7/7/2015
University of Puerto Rico School of Medicine Medical Sciences Campus
3353
mi
from 91732
San Juan,
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
CCOP - Mayo Clinic Scottsdale Oncology Program
358
mi
from 91732
Scottsdale, AZ
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
CCOP - Mayo Clinic Scottsdale Oncology Program
358
mi
from 91732
Scottsdale, AZ
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
Mayo Clinic
2135
mi
from 91732
Jacksonville, FL
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
Mayo Clinic
2135
mi
from 91732
Jacksonville, FL
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
CCOP - Illinois Oncology Research Association
1616
mi
from 91732
Peoria, IL
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
CCOP - Illinois Oncology Research Association
1616
mi
from 91732
Peoria, IL
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
CCOP - Carle Cancer Center
1685
mi
from 91732
Urbana, IL
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
CCOP - Carle Cancer Center
1685
mi
from 91732
Urbana, IL
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
CCOP - Iowa Oncology Research Association
1422
mi
from 91732
Des Moines, IA
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
CCOP - Iowa Oncology Research Association
1422
mi
from 91732
Des Moines, IA
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
Siouxland Hematology-Oncology
1303
mi
from 91732
Sioux City, IA
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
Siouxland Hematology-Oncology
1303
mi
from 91732
Sioux City, IA
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
CCOP - Wichita
1182
mi
from 91732
Wichita, KA
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
CCOP - Wichita
1182
mi
from 91732
Wichita, KA
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
CCOP - Michigan Cancer Research Consortium
1926
mi
from 91732
Ann Arbor, MI
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
CCOP - Michigan Cancer Research Consortium
1926
mi
from 91732
Ann Arbor, MI
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
CCOP - Duluth
1610
mi
from 91732
Duluth, MN
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
CCOP - Duluth
1610
mi
from 91732
Duluth, MN
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
Mayo Clinic Cancer Center
1524
mi
from 91732
Rochester, MN
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
Mayo Clinic Cancer Center
1524
mi
from 91732
Rochester, MN
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
CCOP - Missouri Valley Cancer Consortium
1297
mi
from 91732
Omaha, NE
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
CCOP - Missouri Valley Cancer Consortium
1297
mi
from 91732
Omaha, NE
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
CCOP - Merit Care Hospital
1416
mi
from 91732
Fargo, ND
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
CCOP - Merit Care Hospital
1416
mi
from 91732
Fargo, ND
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
Altru Cancer Center
1444
mi
from 91732
Grand Forks, ND
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
Altru Cancer Center
1444
mi
from 91732
Grand Forks, ND
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
CCOP - Toledo Community Hospital
1936
mi
from 91732
Toledo, OH
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
CCOP - Toledo Community Hospital
1936
mi
from 91732
Toledo, OH
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
CCOP - Oklahoma
1252
mi
from 91732
Tulsa, OK
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
CCOP - Oklahoma
1252
mi
from 91732
Tulsa, OK
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
CCOP - Geisinger Clinic and Medical Center
2296
mi
from 91732
Danville, PA
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
CCOP - Geisinger Clinic and Medical Center
2296
mi
from 91732
Danville, PA
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
Rapid City Regional Hospital
1049
mi
from 91732
Rapid City, SD
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
Rapid City Regional Hospital
1049
mi
from 91732
Rapid City, SD
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
CCOP - Sioux Community Cancer Consortium
1314
mi
from 91732
Sioux Falls, SD
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
CCOP - Sioux Community Cancer Consortium
1314
mi
from 91732
Sioux Falls, SD
Click here to add this to my saved trials
A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas
A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas
Status: Enrolling
Updated:  7/7/2015
Leland Stanford Junior University
328
mi
from 91732
Stanford, CA
A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas
A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas
Status: Enrolling
Updated: 7/7/2015
Leland Stanford Junior University
328
mi
from 91732
Stanford, CA
Click here to add this to my saved trials
A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas
A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas
Status: Enrolling
Updated:  7/7/2015
Yale University School of Medicine
2486
mi
from 91732
New Haven, CT
A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas
A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas
Status: Enrolling
Updated: 7/7/2015
Yale University School of Medicine
2486
mi
from 91732
New Haven, CT
Click here to add this to my saved trials
A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas
A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas
Status: Enrolling
Updated:  7/7/2015
Kansas City Cancer Center
1333
mi
from 91732
Lenexa, KA
A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas
A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas
Status: Enrolling
Updated: 7/7/2015
Kansas City Cancer Center
1333
mi
from 91732
Lenexa, KA
Click here to add this to my saved trials
A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas
A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas
Status: Enrolling
Updated:  7/7/2015
Dana-Farber Cancer Institute
2578
mi
from 91732
Boston, MA
A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas
A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas
Status: Enrolling
Updated: 7/7/2015
Dana-Farber Cancer Institute
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas
A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas
Status: Enrolling
Updated:  7/7/2015
Boston University Medical Center
2578
mi
from 91732
Boston, MA
A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas
A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas
Status: Enrolling
Updated: 7/7/2015
Boston University Medical Center
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas
A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas
Status: Enrolling
Updated:  7/7/2015
NYU Medical Center
2434
mi
from 91732
New York, NY
A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas
A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas
Status: Enrolling
Updated: 7/7/2015
NYU Medical Center
2434
mi
from 91732
New York, NY
Click here to add this to my saved trials
A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas
A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas
Status: Enrolling
Updated:  7/7/2015
Cleveland Clinic Foundation
2033
mi
from 91732
Cleveland, OH
A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas
A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas
Status: Enrolling
Updated: 7/7/2015
Cleveland Clinic Foundation
2033
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas
A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas
Status: Enrolling
Updated:  7/7/2015
M.D. Anderson Cancer Center
1357
mi
from 91732
Houston, TX
A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas
A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas
Status: Enrolling
Updated: 7/7/2015
M.D. Anderson Cancer Center
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas
A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas
Status: Enrolling
Updated:  7/7/2015
Hopitaux du Haut Leveque
2134
mi
from 91732
Pessac,
A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas
A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas
Status: Enrolling
Updated: 7/7/2015
Hopitaux du Haut Leveque
2134
mi
from 91732
Pessac,
Click here to add this to my saved trials
Study of Psychosexual Impact of Cancer-Related Infertility in Women: Third Party Reproductive Assistance
Cross-Sectional Study of Psychosexual Impact of Cancer-Related Infertility in Women: Third Party Reproductive Assistance
Status: Enrolling
Updated:  7/7/2015
Memorial Sloan Kettering Cancer Center
2434
mi
from 91732
New York, NY
Study of Psychosexual Impact of Cancer-Related Infertility in Women: Third Party Reproductive Assistance
Cross-Sectional Study of Psychosexual Impact of Cancer-Related Infertility in Women: Third Party Reproductive Assistance
Status: Enrolling
Updated: 7/7/2015
Memorial Sloan Kettering Cancer Center
2434
mi
from 91732
New York, NY
Click here to add this to my saved trials
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated:  7/9/2015
UCLA's Jonsson Comprehensive Cancer Center
13
mi
from 91732
Los Angeles, CA
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated: 7/9/2015
UCLA's Jonsson Comprehensive Cancer Center
13
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated:  7/9/2015
Children's Hospital of Orange County
21
mi
from 91732
Orange, CA
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated: 7/9/2015
Children's Hospital of Orange County
21
mi
from 91732
Orange, CA
Click here to add this to my saved trials
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated:  7/9/2015
The Children's Hospital, B115, University of Colorado Health Sciences Center
825
mi
from 91732
Aurora, CO
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated: 7/9/2015
The Children's Hospital, B115, University of Colorado Health Sciences Center
825
mi
from 91732
Aurora, CO
Click here to add this to my saved trials
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated:  7/9/2015
Northwestern University School of Medicine, Stem Cell Transplant Program, Children's Memorial Hospital
1729
mi
from 91732
Chicago, IL
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated: 7/9/2015
Northwestern University School of Medicine, Stem Cell Transplant Program, Children's Memorial Hospital
1729
mi
from 91732
Chicago, IL
Click here to add this to my saved trials
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated:  7/9/2015
Cardinal Bernardin Cancer Center, Loyola University Stritch School of Medicine
1719
mi
from 91732
Maywood, IL
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated: 7/9/2015
Cardinal Bernardin Cancer Center, Loyola University Stritch School of Medicine
1719
mi
from 91732
Maywood, IL
Click here to add this to my saved trials
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated:  7/9/2015
The Cancer Center, Hackensack University Medical Center
2430
mi
from 91732
Hackensack, NJ
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated: 7/9/2015
The Cancer Center, Hackensack University Medical Center
2430
mi
from 91732
Hackensack, NJ
Click here to add this to my saved trials
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated:  7/9/2015
Cornell University, Joan & Sanford I. Weill Medical College
2434
mi
from 91732
New York, NY
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy
Status: Enrolling
Updated: 7/9/2015
Cornell University, Joan & Sanford I. Weill Medical College
2434
mi
from 91732
New York, NY
Click here to add this to my saved trials